MEINOX is a biopharmaceutical company developing innovative and personalized therapeutics for the treatment of patients with MEIS+ cancers.
Our founder and president, Dr. Fatih Kocabas, established MEINOX as a startup company to develop and commercialize small molecule inhibitors of MEINOX family, in particular MEIS proteins. Our team includes experts in project management, drug discovery, and cancer biology. We seek to share our expertise and proprietary small molecule platforms that can be deployed in collaboration with strategic partners to develop next generation therapeutics for various cancer and malignancies. We have developed first-in-class, selective, drug-like small molecule MEIS inhibitors. Studies demonstrated that blocking the MEIS proteins in tumors could:
Block cancer cell growth
Enhance cancer death through induction of apoptosis
